Table 1.
Immune checkpoint inhibitors approved by the Food and Drug Administration and the China National Drug Administration
| Drug | Target | Indications | ||
|---|---|---|---|---|
| FDA | NMPA | |||
| Pembrolizumab | PD-1 | Melanoma | Melanoma | |
| Advanced non-small-cell lung cancer | Non-small-cell lung cancer | |||
| Squamous-cell carcinoma of the head and neck | Squamous-cell carcinoma of the head and neck | |||
| Non-muscle invasive bladder cancer | Esophageal squamous cell carcinoma | |||
| Advanced renal-cell carcinoma | Hepatocellular carcinoma | |||
| Advanced colorectal cancer with MSI-H or dMMR | Colorectal cancer with MSI-H or dMMR | |||
| Solid tumors with MSI-H or dMMR | ||||
| High-risk early-stage or advanced triple-negative breast cancer | ||||
| Classic Hodgkin's lymphoma | ||||
| Advanced gastric cancer | ||||
| Advanced endometrial cancer | ||||
| Primary mediastinal B-cell lymphoma | ||||
| Advanced hepatocellular carcinoma | ||||
| Advanced esophageal carcinoma | ||||
| Uroepithelial carcinoma | ||||
| Advanced Merkel cell carcinoma | ||||
| Squamous-cell carcinoma of skin | ||||
| Nivolumab | PD-1 | Advanced non-small-cell lung cancer | Non-small-cell lung cancer | |
| Advanced Melanoma | Squamous-cell carcinoma of the head and neck | |||
| Squamous-cell carcinoma of the head and neck | Gastric cancer/adenocarcinoma of esophagogastric junction | |||
| Advanced renal-cell carcinoma | Advanced gastric cancer | |||
| Advanced hepatocellular carcinoma | Malignant pleural mesothelioma | |||
| Advanced bladder cancer | Esophageal squamous cell carcinoma | |||
| Classic Hodgkin's lymphoma | ||||
| Colorectal cancer with MSI-H or dMMR | ||||
| Malignant pleural mesothelioma | ||||
| Gastric or gastroesophageal junction cancer or esophageal adenocarcinoma | ||||
| Cemiplimab | PD-1 | Cutaneous Squamous Cell Carcinoma, | ||
| Non-small cell lung cancer | ||||
| Toripalimab | PD-1 | Melanoma, | ||
| Nasopharyngeal carcinoma | ||||
| Esophageal cancer | ||||
| Uroepithelial carcinoma | ||||
| Sintilimab | PD-1 | Hodgkin's lymphoma,lung cancer | ||
| Esophageal Cancer | ||||
| Hepatocellular carcinoma | ||||
| Gastric cancer/adenocarcinoma of esophagogastric junction | ||||
| Hepatocellular carcinoma | ||||
| Camrelizumab | PD-1 | Classic Hodgkin's lymphoma | ||
| Esophageal squamous carcinoma | ||||
| non-small-cell lung cancer | ||||
| Hepatocellular carcinoma | ||||
| Nasopharyngeal carcinoma | ||||
| Tislelizumab | PD-1 | Hodgkin's lymphoma | ||
| Lung cancer | ||||
| Hepatocellular carcinoma | ||||
| Uroepithelial carcinoma | ||||
| Solid tumors with MSI-H or dMMR | ||||
| Penpulimab | PD-1 | Hodgkin's lymphoma | ||
| Serplulimab | PD-1 | Solid tumors with MSI-H or dMMR | ||
| Pucotenlimab | PD-1 | Solid tumors with MSI-H or dMMR | ||
| Retifanlimab | PD-1 | Metastatic or recurrent locally advanced Merkel cell carcinoma | ||
| Atezolizumab | PD-L1 | Extensive stage small cell lung cancer | ||
| Metastatic non-small-cell lung cancer | ||||
| Advanced triple-negative breast cancer | ||||
| Locally advanced or metastatic uroepithelial carcinoma | ||||
| Advanced Melanoma | ||||
| Durvalumab | PD-L1 | Non-small-cell lung cancer | ||
| Small cell lung cancer | ||||
| Uroepithelial carcinoma. | ||||
| Cholangiocarcinoma | ||||
| Envafolimab | PD-L1 | Solid tumors with MSI-H or dMMR | ||
| Zimberelimab | PD-L1 | Hodgkin's lymphoma | ||
| Sugemalimab | PD-L1 | Hepatocellular carcinoma Non-Small-Cell Lung Cancer |
||
| Solid tumors with MSI-H or dMMR | ||||
| Avelumab | PD-L1 | Uroepithelial carcinoma | ||
| Advanced renal-cell carcinoma | ||||
| Merkel cell carcinoma | ||||
| Ipilimumab | CTLA-4 | Melanoma | ||
| Tremelimumab | CTLA-4 | Hepatocellular carcinoma | ||
| Non-small-cell lung cancer | ||||
| Cadonilimab | PD-1/CTLA4 | Cervical Cancer | ||
| Relatlimab | LAG-3 | Melanoma | ||
Note: FDA, Food and Drug Administration; NMPA, National Medical Products Administration; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; CTLA-4, cytotoxic T-lymphocyte antigen 4; LAG-3, lymphocyte activation gene-3. Data as of: March 2023.